The FDA determined this week that Cordis’ recent recall of several versions of its Super Torque angiographic catheters meet the criteria of a Class I recall, a label reserved for those the ...

The FDA has cleared Cordis' EMPIRA and EMPIRA NC RX PTCA dilatation catheters for the treatment of coronary artery disease. The U.S. launch is expected early next year. "The EMPIRA Balloon ...

SAN FRANCISCO--(BUSINESS WIRE)--Cordis Corporation today announced EMPIRA™ and EMPIRA™ NC RX PTCA Dilatation Catheters have received 510(k) regulatory clearance for the treatment of coronary ...